[
    [
        {
            "time": "",
            "original_text": "博雅生物回复问询函：公司血液制品业务毛利率高于可比上市公司平均水平，具有合理性 问询",
            "features": {
                "keywords": [
                    "博雅生物",
                    "血液制品",
                    "毛利率",
                    "高于",
                    "可比上市公司",
                    "合理性"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "博雅生物回复问询函：公司血液制品业务毛利率高于可比上市公司平均水平，具有合理性 问询",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]